A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|DRUG: Perjeta (EU origin) 420 mg in 14 mL Injection|DRUG: Perjeta (US origin) 420 mg in 14 mL Injection
Sponsor: EirGenix, Inc.
Collaborators: Sacura GmbH